SCHEMBL306389

SCHEMBL306389

CCCC(C)CC[CH]CCC(C)CC

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
ALDH1A1 P00352 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16594818 0.87 TSHR (0.31) TSHR
SCHEMBL9414024 0.86 TSHR (0.37) TSHR
SCHEMBL9029419 0.86 TSHR (0.37) TSHRALDH1A1ALOX15
SCHEMBL28600057 0.82 TSHR (0.42) TSHRALDH1A1ALOX15
SCHEMBL2379126 0.82 LMNA (0.32)
SCHEMBL3885519 0.82 TSHR (0.42) TSHRALDH1A1ALOX15
SCHEMBL6061890 0.81 ADH1B (0.36) TSHR
SCHEMBL4977381 0.81 LMNA (0.39) TSHRALDH1A1ALOX15
SCHEMBL4634958 0.81 ADH1B (0.36) TSHR
SCHEMBL24224784 0.81 TSHR (0.50) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113521299-B Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-114126606-B Method for dispersing a biofilm comprising gram-negative bacteria Q生物股份有限公司 2024-06-21 CN disclosed
CN-118213618-A Electrolyte additive, electrolyte, lithium ion battery and electronic device 蔚来电池科技(安徽)有限公司 2024-06-18 CN disclosed
CN-115052596-B ADAMTS inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-14 CN disclosed
CN-118027131-A Salt of steroid derivative regulator and crystal form thereof 上海翰森生物医药科技有限公司 2024-05-14 CN disclosed
CN-117986249-A Pyrazole derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-05-07 CN disclosed
CN-117964682-A Dolastatin derivative and preparation method and application thereof 杭州爱科瑞思生物医药有限公司 2024-05-03 CN disclosed
US-20240132728-A1 Bio-Based Coalescing Solvents BATTELLE MEMORIAL INSTITUTE 2024-04-25 US disclosed
CN-117917409-A Crystal form of heterocyclic derivative inhibitor and preparation method and application thereof 上海翰森生物医药科技有限公司 2024-04-23 CN disclosed
CN-113905743-B CD73 inhibitors and therapeutic uses thereof 江苏恒瑞医药股份有限公司 2024-04-16 CN disclosed
US-6864261-B2 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2005-03-08 US disclosed
WO-2005019353-A2 COPOLYMER SURFACTANTS COLUMBIA INSURANCE COMPANY (US) 2005-03-03 WO disclosed
US-20050039635-A1 Copolymer surfactants BENJAMIN MOORE & CO. 2005-02-24 US disclosed
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides APPLIED BIOSYSTEMS, LLC 2005-02-03 US disclosed
WO-2004104054-A1 POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-12-02 WO disclosed
US-20040127501-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2004-07-01 US disclosed
WO-2004029044-A1 PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS EURO-CELTIQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040053914-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-18 US disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed
EP-0086647-A2 Pyrimidone compounds, their preparation, and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1983-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053914-A1 Therapeutic agents useful for treating pain SMN1; SMN2, OPRM1, PSEN1 TSHR 2139/4885ALDH1A1 416/4885ALOX15 587/4885
US-20040127501-A1 Therapeutic agents useful for treating pain CACNA1A, GRIN2A, HTT TSHR 1813/4885ALDH1A1 516/4885ALOX15 935/4885
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides POLI, PCNA, POLL TSHR 4259/4885ALDH1A1 3357/4885ALOX15 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.